Author Archive Amelia Whitehart
Jason and Whitney Johns, PURE Independent Business Owners, surpass $100,000 in earnings
PURE Independent Business Owners (IBOs), Jason and Whitney Johns, have achieved the rank of Presidential through the company’s PURE Prosperity Compensation Plan.
This prestigious rank of Presidential is now more rewarding than ever with the launch of the company’s PURE Rank Bonus program in April 2017. The Johns received a PURE Presidential Rank Bonus of $35,000 USD, in addition to their PURE Blue Diamond Rank Bonus of $25,000 USD last week. These are additional bonuses outside of PURE’s Prosperity Compensation Plan. Their total earnings for the eight weeks since joining PURE has been over $100,000 USD.*
Achieving this level puts the Johns among the top leaders at PURE. This achievement speaks to the momentum currently experienced by the company and driven by the field leaders of PURE.
Jason and Whitney Johns live in Celina, Texas with their two children. Jason is a high school coach in north Texas. Whitney owns a small boutique. They have been building their PURE business for seven weeks. Whitney’s favorite product is grape ENERGY.
“Teamwork is the name of the game! The support I’ve received from my upline has been remarkable. Not only are we impacting our own lives, but we are changing the lives of others in a big way,” said Whitney Johns. “If you have not gotten involved with the PURE opportunity, get involved fast. It is life changing.”
“In the short time they’ve been with PURE, the Johns have built a strong foundation that has propelled them into a leadership position. They are a fine example of commitment and perseverance, and have the necessary skills that will take them far. I congratulate them in achieving this milestone.” – Daren Hogge, PURE CEO
The PURE opportunity gives people the chance to earn weekly residual income. In addition, through the PURE Rank Bonus, IBOs receive bonuses and incentives. Beginning at the rank of Platinum Director, awards through the PURE Rank Bonus program range from $1,000 USD all the way to an amazing $250,000 USD.* To date, PURE’s total payout through the program is $239,500.
About PURE
PURE: People United Reaching Everyone is a leading innovator in health and wellness products. They believe people can achieve Whole Health with a balance of physical health, financial health, and purpose. PURE is a global company with offices in the U.S., Japan, Taiwan, and Korea. Headquarters is in Frisco, Texas. For more information on the products or business opportunity, visit livepure.com
*The earnings of the distributors in this publication are not necessarily representative of the income, if any, that a PURE distributor can or will earn through his or her participation in the PURE Prosperity compensation plan. These figures should not be considered as guarantees or projections of your actual earnings or profits. Success with PURE results only from successful sales efforts, which require hard work, diligence and leadership. Your success will depend upon how effectively you exercise these qualities. For detailed information on the PURE Prosperity compensation plan and distributor income averages, please visit the opportunity section of the PURE website at http://www.livepure.com/rewards-compensation.
Digimarc Recognized as Technology Leader
Today Digimarc Corporation (NASDAQ: DMRC), inventor of the Digimarc Discover? platform featuring the imperceptible Digimarc Barcode, announced the company has been recognized for driving innovative solutions into the retail sector. Digimarc is named by ABI Research as a Smart Retail Hot Tech Innovator for 2017. The company was also recognized in IEEE Spectrum for its intellectual property, ranking third for its patent portfolio in the computer software category behind only Microsoft and VMWare, and ahead of software powerhouses including Adobe, Citrix, Oracle, SAP and Symantec.
“Our vision is to enrich everyday living through our patented technologies and applications such as Digimarc Barcode,” said Bruce Davis, chief executive officer, Digimarc. “We have a long tradition of technology innovation and a computing platform that enables future application development and growth by our customers and partners. It’s gratifying to see this recognition of our industry-leading innovation.”
ABI Research identified solutions and innovative companies that are enabling a retail revolution. According to the firm, the selection criteria for “retail hot tech innovators” identified the companies that are the fastest growing in the retail technology industry based on the number of implementations internationally, and the amount of funds raised from capital investors that will continue to fuel their growth.
In “Patent Power 2017,” IEEE Spectrum reports on intellectual property from leading companies. Its Pipeline Power rating ranks patent portfolios by number of U.S. patents granted in the most recent full year (2016) and quality, as measured by statistical assessment of important qualities such as growth, impact, originality and general applicability.
Additional information about Digimarc Barcode can be viewed here.
About Digimarc
Digimarc Corporation (NASDAQ: DMRC) is a pioneer in the automatic identification of everyday objects such as product packaging and virtually any media, including print, images and audio. Based on the patented Intuitive Computing Platform (ICPT), Digimarc provides innovative and comprehensive automatic recognition technologies to simplify search, and transform information discovery through unparalleled reliability, efficiency and security. Digimarc has a global patent portfolio, which includes over 1,100 granted and pending patents. These innovations include state-of-the-art identification technology, Digimarc Barcode, as well as Digimarc Discover? software for barcode scanning and more. Digimarc is based in Beaverton, Oregon, with technologies deployed by major retailers and consumer brands, central banks, U.S. states, film companies and professional sports franchises, among others. Visit digimarc.com and follow us @digimarc to learn more about The Barcode of EverythingT.
SOURCE Digimarc Corporation
Cutting Supplements for Women
This article will detail a lot of the methods and products used by women bodybuilders to achieve great fitness results while being health safe.
So many questions …. What are the best steroids for women to use and what are the potential benefits and side effects? Almost every female bodybuilder has questions about steroids women can use. Steroids have become somewhat accepted for use by men, at least socially. But there are still many questions about the efficacy.
Like men, women are interested in taking steroids too. There are many reasons for this, but the most common is to get a slim and muscular look, and get rid of fat. Women are more concerned about their physique, that’s why more and more women are used chemical bodybuilders for building a great body.
Legal Anavar is a safe, natural, extremely effective legal alternative to the prescription steroid Oxandrolone, also known as Anavar and goes by many other street names. This legal anabolic is manufactured with the exact same goals in mind as its pharmaceutical counterpart, but without the dangerous side.
A woman’s metabolism is different than a man’s. The fact is, women retain more fat than men. There are different supplements available for women, a popular product is one made by CrazyBulk. Detailed view : legal steroids safe for women
There are many women who are genetically gifted, but those women are few and far between. Most women do not have perfect genetics and struggle when trying to lose weight, burn fat, and firm up their muscles. In order to get a ripped and shredded most women will not tell you that besides diet and exercise, they use a variety of performance enhancement drugs (steroids).
Anabolic steroids are commonly used by fitness models, yes the ugly truth is, women tend to carry around more body fat than men, in order for women to stimulate their metabolism and burn fat there are 3 steroids women will take to help burn fat and maintain a lean body.
Most women are not going to compete in a fitness or bodybuilding competition, however, many want to have a great looking body, taking steroids does have side effects, however, there are safe steroid alternatives that can offer similar benefits. Legal steroids offer the same benefits by mimicking the effects of anabolic steroids.
Unfortunately, most bodybuilding supplements target male athletes and bodybuilders, what most companies do not realize is that there are just as many women that look for supplements to help improve their physique and performance. Unlike men, women have a harder time eliminating body fat. That is why some supplement companies have turned their focus to female bodybuilders and fitness models.
We all carry weight in different places and the last place where that weight seems to come off is the stomach or abdominal area, however it is not practical to think that we can completely eat our way to shredded abs, sure you can eat clean healthy foods but that is not the complete secret to shredded abs. What we can do is watch what we eat and eliminate foods that provoke our body to store fat.
The body needs protein and lean protein acts as a thermogenic that can help burn fat, it has been proven time and time again that high protein diets are more effective than low calorie or low fat diets, this means eating plenty of fish, chicken, lean beef and green leafy vegetables.
The goal of a cutting cycle is to maintain as much muscle as you can while eliminating body fat. Everyone has muscle, however, the only way to show it off is by getting rid of the fat that is covering up the muscle.
What is Methodology X
Methodology X is a cutting edge 28 day home workout that is specially tailored for women. The Book is written by Dan Roberts who has been training famous supermodels and A -list actresses for the last two decades. The Book comes in an electronic format (E-Book) that can easily be downloaded to any Apple or Android device including any computer (laptop) tablet or smartphone. Read more on the topic : fitness model competition training
What is BlackWolf Hunt?
BlackWolf Hunt for women is a premium workout supplement for women to get you through the toughest training sessions. Inta-Workout means you take it while you train. It will keep you strong and help you maintain energy levels no matter how hard the workout is. BlackWolf Hunt helps carry you through the rest of the way so you can train strong with plenty of energy. Read more on the topic : Best pre workout supplements
Steroids can be a fast way to achieve a jaw-dropping physique but sometimes it really isn’t worth the risk. For health reasons, it’s probably a good idea to stay away from them and that’s why supplements are so popular, they are not that strong but they do give the athlete and edge.
The famous HIV virus discoverer Robert Gallo joined Medisun Medical Group
The famous American virologist – HIV virus discoverer Robert Gallo joined Medisun Medical Groupedisun
Bringing the best cancer and AIDS treatment technologies to China
Robert Gallo, a famous American virologist, joined Medisun Medical Groupedisun
In February 2017, Medisun Medical Group officially announced the appointment of Robert Charles Gallo, a famous American virologist, as a member of the board of directors of the group.
Dr. Robert Charles Gallo
Dr. Gallo is a famous American virologist whose best-known contribution is the discovery of the first human retrovirus (HTLV1, and HTLV2). In 1983, HTLV3 was discovered, which was later called the HIV, a virus that causes AIDS. He also studied the cytokine leukocyte 2, and in 1986 studied the pathogen human rash type 6 virus in children with acute rash. In 1982 and 1984, he received the Lasker Basic Medical Research Award (known as the “Nobel Prize in the United States”), the Charles Mott Award (Tumor Prevention Contribution Award) in 1984, and the Dickson International Award in 1985, 1988. Received the National Science and Technology Outstanding Contribution Award from Japan. Dr. Gallo is currently the Director of the Institute of Human Virology (IHV) at the University of Maryland and the founder and chief scientist of the Global Virus Network (GVN). He has served in the National Cancer of the United States. The National Cancer Institute has served as the director of the Laboratory of Cancer Cell Biology for 30 years. Dr. Gallo proposed the theory that the tumor system is caused by viruses and gradually improved its academic structure and clinical research.
Mr. Terry L. Lierman, founder of the US FDA, joined Medisun
At the same time , Mr.Terry L. Lierman entered the board of Medisun. Mr. Lierman is the founder of Summit Global Ventures and the CEO of Health Ventures LLC.Mr. Lierman has served on the US Senate Appropriations Committee and served as Director of the Sub-Committee on Labor Health and Human Services (HHS) Grants. Mr. Lierman is also the founder of Research America and NIH (National Institutes of Health) / FDA (US Food and Drug Administration) Board of Directors, and serves as the majority leader and member of the House of Representatives. He began his career in the health field of the NIH (National Institutes of Health) in 1971, where he assisted with budget and policy development, grants and contracts. For the past four decades, he has combined entrepreneurs and political talent in a variety of businesses.From leadership positions in the US Senate Appropriations Committee, founding companies and non-profit organizations, to promote health care advocacy, to lead and serve as chairman of the Maryland Democratic Party.
Mr.Terry L.Lierman
Chairman Medisun Wang Xiaofeng joined the Board of Directors of the Institute of Human Virology and the International Virus Alliance
At the same time that two world-class companies joined Medisun, Mr. Wang Xiaofeng, Chairman of Medisun Medical Group, was also invited to the Institute of Human Virology (IHV) and the Global Virus Network (GVN) at the University of Maryland as a member of the board of directors. Mr. Wang is the founder and chairman of the Board of Directors of Medisun Medical Group living in Canada and the United States for ten years. He moved to Hong Kong in 1996. Mr. Wang has more than 20 years of experience in the global capital market and medical industry, including industries including Medisunne, internet, education and media. Mr. Wang is currently Chairman of Hong Kong-listed National Investment Fund (01227.HK) and Chairman of Beijing Financial Group.
Mr. Danny Wong
Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as top hospitals and treatment centers.
Medisun invests extensively in the fields of regenerative Medisunne and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun Medical has a long-term cooperation plan with the US-Australia Clinic, the Harvard University Stem Cell Institute, and the Johns Hopkins Medical School Life Science Center to jointly invest in regenerative Medisunne and stem cell therapy technology, with Medisun as a co-operative business. The Medisun holding entity and holds global intellectual property rights.
The Medisun Reproductive Medisunne Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments. As the Asian service organization of Mayo Clinic, the center provides Mayo remote consultation and secondary treatment to enable Chinese patients to enjoy authoritative medical services without leaving the country. 3,300 biomedical tests provide the most predictable health protection for customers’ health, adding more than 300 new testing items each year.
MEDISUN REGENERATIVE MEDICAL CENTER | CANCER TREATMENT CENTER | ANTI-AGING CENTER
Medisun Medical Laboratory (Hong Kong)
Medisun Medical Laboratory (Hong Kong)
Medisun announced that he will join the Biden Cancer Lunar Plan
At the end of 2016, Medisun announced that he would join the “Cancer Moon Plan” initiated by former US Vice President Biden. The “Cancer Moon Plan” was proposed by former US President Obama in early 2016 and was initiated by former Vice President Biden. The goal is to shorten the work schedule for cancer-related prevention, diagnosis, treatment and care that was expected to be completed in 5 years. Aiming to achieve 20,000 cancer treatments worldwide by 60 programs by 2020.
Dr. Gallo and Mr. Lierman will lead Medisun’s clinical research implementation, medical technology and project selection, medical resource introduction, etc., and bring the best technology in the world to China, highlighting the inevitable trend of China’s participation in the world’s most advanced technology research and development. . At the same time, Medisun’s clinical research bases in Hong Kong, Beijing, Shanghai, Guangzhou and Tokyo will participate in the world’s most advanced clinical research.
Dr. Gallo and Mr. Lierman joined Medisun and Chairman Wang Xiaofeng to enter the IHV and GVN Board of Directors, indicating that Medisun will work with IHV and GVN to make valuable preparations for the cancer landing program and to fully participate in the global research and development of cancer treatment.
The Human Virology Institute (IHV) is the world’s first research center that combines basic science, epidemiology and clinical research disciplines to accelerate the diagnosis and treatment of chronic viruses and immune diseases (mostly HIV, AIDS the reason). IHV’s laboratory is a US key laboratory that receives more than $200 million in annual US research funding.
Founded in 1996 as a partner of the University of Maryland, IHV is a research institute at the University of Maryland School of Medisun, bringing together a globally recognized and world-renowned expert in human virology. The IHV was co-founded by Robert Gallo (Director of IHV) and William Blattner.MD. The IHV also includes the Animal Model Department, the Basic Science Department and the Vaccine Research Department.
The institute has a variety of laboratory and patient care facilities located in Baltimore, Maryland. IHV has created an environment of close collaboration between multidisciplinary research, education and clinical research and development, accelerating scientific understanding of the incidence of HIV/AIDS, and developing interventions to curing cancers of HIV and viruses possible.
IHV’s research focuses on how to use the body’s natural chemistry to its own therapeutic potential, and to discover biotherapeutics that are less toxic to the body and more economical for the public. IHV is also committed to developing effective therapeutic and preventive vaccines that are dedicated to ending the AIDS epidemic.
IHV has more than 300 employees, including 70 professors, whose research focuses on chronic human viral infections and diseases. Currently, more than 75% of the Institute’s clinical and research work addresses HIV infection, but also includes hepatitis C virus, human T-cell leukemia virus 1 and 2, human papillomavirus, herpes virus and cancer research. The patient base of IHV has grown from just 200 patients to about 6,000 in Baltimore, and nearly 1 million in 6 African and 1 Caribbean countries.
The Global Network of Viruses (GVN) is a global organization for the research of viral diseases. It is a consortium of authoritative virologists from more than 20 countries around the world. It is dedicated to the research, development of drugs and vaccines to prevent diseases and death. GVN is the only single organization in the world that has special research in all areas of the virus. GVN brings together the world’s best medical virology experts to focus on difficult scientific issues around the world. The strength of GVN lies in its global reach, the depth of science, and its vision to address the viral challenges facing humanity.
GVN achieves its goals through three strategic action platforms:
Support research
Public education
Advocate a statement supporting the global virus network
Established in Washington, DC, the organization supports the goals and ideals of a global virus network, actively trains younger generations of medical virologists, and provides advice to governments or NGOs on viral diseases to fill the current international health development important needs.
Source: http://www.medisun.hk/
Élodie D’Ambrosio : Une Jeune Talent Prometteuse dans le Monde de l’Animation
Élodie D’Ambrosio : Une Jeune Talent Prometteuse dans le Monde de l’Animation
En 2015, l’animation continue de captiver les audiences à travers le monde, et parmi les talents émergents de cette industrie dynamique, Élodie D’Ambrosio se distingue comme une créatrice innovante avec une vision artistique unique. Bien que jeune, son travail commence à attirer l’attention des professionnels et des passionnés d’animation, signalant le début d’une carrière prometteuse.
Une Formation Solide
Élodie D’Ambrosio a toujours été fascinée par le monde du dessin et du cinéma d’animation. Dès son plus jeune âge, elle démontre un talent précoce pour le dessin, ce qui la pousse à poursuivre des études en design graphique. En 2010, elle complète son parcours à l’École des Gobelins, une institution renommée pour ses programmes en animation. Cette formation rigoureuse lui permet d’acquérir les compétences nécessaires pour se faire un nom dans l’industrie.
Un Style Visuel Distinctif
Ce qui distingue le travail d’Élodie D’Ambrosio est son style visuel unique. Influencée par les classiques de l’animation française et internationale, elle développe une approche personnelle qui marie la fluidité des animations traditionnelles avec les techniques numériques modernes. Sa capacité à créer des personnages expressifs et des environnements visuellement captivants est déjà perceptible dans ses premières œuvres, attirant l’attention pour leur originalité et leur sensibilité artistique.
Premiers Projets et Récompenses
Élodie D’Ambrosio se fait connaître pour ses premiers courts-métrages qui commencent à être présentés dans des festivals locaux et internationaux. Son court-métrage “Éclats de Rêves”, qui explore les thèmes du rêve et de la réalité à travers une animation délicate et imaginative, reçoit des critiques positives pour son innovation visuelle et sa narration émotive. Bien que ce soit le début de sa carrière, ses projets montrent déjà une maîtrise impressionnante de l’animation et une capacité à captiver l’audience.
Une Présence Grandissante
En plus de ses projets personnels, Élodie commence à travailler en tant qu’animatrice dans des studios renommés, où elle contribue à divers projets, allant des publicités animées aux productions pour enfants. Sa capacité à collaborer avec des équipes diverses et à s’adapter à différents styles montre son professionnalisme et son potentiel dans le domaine. Les premiers signes de son influence croissante dans l’industrie deviennent apparents, faisant d’elle une créatrice à suivre de près.
Engagement envers l’Éducation
L’engagement d’Élodie D’Ambrosio envers l’éducation et la promotion de l’animation est également notable. Elle participe à des ateliers pour jeunes créateurs et donne des conférences sur l’animation, partageant son expertise et sa passion avec la prochaine génération de talents. Cet engagement démontre non seulement sa volonté de contribuer à l’évolution du domaine, mais aussi son désir de rendre l’animation accessible à un public plus large.
Perspectives d’Avenir
Alors que 2015 progresse, Élodie D’Ambrosio est bien positionnée pour continuer à développer son influence dans le monde de l’animation. Avec des projets en cours et une vision artistique en constante évolution, elle est sur le point de jouer un rôle significatif dans l’avenir de l’industrie. Les amateurs d’animation et les professionnels du secteur attendent avec impatience de voir comment elle continuera à repousser les limites de l’art et de la narration animée.
En résumé, Élodie D’Ambrosio est une jeune talentueuse dont le travail et la passion pour l’animation commencent à faire des vagues en 2015. Sa créativité, son engagement et son style distinctif font d’elle une figure montante à surveiller dans les années à venir.
Mayo and Medisun have joined forces to enter the Chinese medical market
Medisun Medical Group 2015-01-26,
Taking the first year of China’s medical reform in 2015 as an opportunity, Mayo and Medisun have joined forces to enter the Chinese medical market in large numbers. It can be said that it is at the right time. Dr. Cao Shengyu, President of Medici Medical Group, former General Manager of Hong Kong Queen Elizabeth Hospital and General Manager of Kowloon China Network and managing the five public hospitals, said: “Based on our experience in investing in hospitals in Hong Kong and China over the past 20 years, and in the new environment of China’s medical system reform, Medisun is confident to introduce Mayo’s advanced medical service system to China and benefit patients. According to the GATT and the planning process of a number of specific work agreements, we will gradually provide Mayo’s medical services from Hong Kong to Beijing and Shanghai.
The establishment of the Mayo affiliated hospital system have truly brought Mayo’s world-class medical care to Chinese patients. Dr. Cao was the President of the China Hospital Society HCA (Hospital Corporation of America), responsible for establishing sino-American joint venture hospital in China.
On January 22, 2015, at the strategic cooperation ceremony between Mayo and Medisun, Mayo President Jeffrey Burton led the Mayo executives to accept the Chinese Song Dynasty Tiansheng Acupuncture Copper Man presented by Chairman Madison
Dr. Zhang Yuanxin, senior vice president of Medisun Medical Group and senior bio-industry analyst on Wall Street in the United States, joined Medisun in recognition of Medisun’s expectations for regenerative medicine and China’s healthcare reform. He said, “The cooperation between Mayo and Medisun began with Medisun’s investment in cutting-edge technologies in regenerative medicine.
The two sides have reached a high consensus on the concept of developing medical services in China. Mayo values Medisun’s strategic position in connecting Hong Kong and connecting things. And Medisun’s existing advanced medical facilities and experienced management team, and reached a long-term cooperation agreement with Medisun. This understanding and understanding laid a solid foundation for the cooperation between the two, and the real benefit is the Chinese patients.
Source: http://www.medisun.hk/
Heart failure patients helped to regain health by Stem Cell Therapy
The International Forum on Heart Failure and Stem Cell Therapies Focus on C-Cure Technology and Launch Ceremony of Phase III Multisite Clinical Trial in China was held jointly by six organizations including Experts Committee of China Council for Medicine International Promotion, National Stem Cell and Regenerative Medicine Industrial Technology Innovation Strategic Alliance, etc on August 25th in Shanghai. The reporter was informed from the forum that the C-Cure technology for the treatment of heart failure through stem cells will make the heart failure patients who are lack of effective treatment regain health and rebirth.
Junbo Ge, Academician from the Chinese Academy of Sciences and Deputy President of Tongji University, has introduced the current situation of heart failure worldwide on the forum, that is, the number of patients worldwide reaches 117 million, among which there are 29.971 million patients in China, accounting for 25.6% of the total. At present, the traditional therapy of end-stage heart failure requires heart transplantation, which not only arouses problems such as too less donors, long waiting time, strong rejection reaction, etc, but also brings huge economic burden to the family or even the society. Academician Ge also says that the scientists are still making unremitting efforts to promote the application of stem cell technology on Chinese people suitably and safely. He also hopes that more administrative departments will support this technology and he believes the future will definitely be the biomedical era.
Dr Andre Terzic from the Center for Regenerative Medicine of the US Mayo Clinic and the experts from the Cardiovascular Center of Belgian Aalst Hospital have introduced the cardiac repair revolution of stem cell technology——C-cure technology and C-CathEZ Catheter on the forum. The C-Cure technology involves aspiration of the patient’s bone marrow and isolation of the mesenchymal stem cell fraction. A unique and proprietary “cardiopoietic cocktail” of proteins is used to differentiate the patient’s mesenchymal stem cells into cardiac progenitor cells, or so called “cardiopoietic cells”. The heart specific stem cells are expanded in vitro and then implanted into the diseased and damaged area of the heart using the C-Cathez delivery device. These implanted cardiac stem cells regenerate and heal the heart that has been injured by myocardial infarction, or heart attack.
C-CathEZ is the world’s most advanced proprietary catheter used for delivery of stem cells to the heart. It is capable of accurately delivering diagnostic and therapeutic agents to the damaged myocardium through a minimally invasive procedure. C-CathEZ navigates to the left ventricle through the aortic arch, and its curved and porous needle stays anchored to the ventricular wall, moving in sync with the ventricular wall motion once it reached the myocardium. The porous needle can also be repositioned for injections of cells into different areas. C-CathEZ enables the injection and distribution of stem cells evenly into the damaged myocardium, resulting in a higher portion of retention of cells. The C-Cure technology and the catheter C-CathEZ have been nominated as finalists for two 2014 European Mediscience Awards, the “Breakthrough Award” and the “Best Technology Award”.
Medisun has established collaborations with the Mayo Clinic, a renowned medical group in the United States, and the two have co-invested in Cardio3 BioSciences, the owner of C-Cure technology and catheter C-CathEZ. At present, C-Cure has been authorized to conduct the Phase III clinical trial in the US and European Union, and the product could potentially be launched globally in 2016. Moreover, the technology of catheter C-CathEZ has obtained authentication and licensing from the EU in April, 2012.
In order to make the stem cell therapy be available to more Chinese heart failure patients, Mesisun Holdings Limited will establish 8 to 10 international multisite clinical bases in Shanghai, Beijing and Guangzhou to carry out the Phase III clinical trial of C-Cure technology in Mainland China. The launch ceremony of developing Phase III clinical trial by the cooperation of Cardio3 and Shanghai East Hospital has been held on the forum. Before that, Medisun Holdings Limited and Beijing Anzhen Hospital has formally launched the cooperation of Phase III clinical trial of C-Cure technology.
Zhongmin Liu, President of the East Hospital of Tongji University says, “The clinical application of stem cell is the dream of a number of clinical doctors and the experts from the stem cell field. With the gradual improvement of the isolation, culture and expansion technology of stem cells as well as the interventional methods for heart failure patients, the clinical application is promising. The East Hospital is looking for a biological cell therapy with more effectiveness and better life quality for the patients, which is able to avoid and delay the heart transplantation, that is, the application of stem cells in the heart failure treatment. Before the stem cell therapy, the heart failure patients rely on the heart transplantation ultimately. However, the time to wait for the heart donor is long, and the patient has to be hospitalized repeatedly, which costs money and makes the patient painful. With this cell technology, combining with technology of minimally invasive catheter, the result of HF treatment may be identified whenever or wherever without spending too much money. It can avoid the patients to be hospitalized repeatedly and can also reduce expenditure, which brings better life for the patients. This cell therapy brings effects that the traditional drug treatment can’t give not only for HF patients, but also for patients with diabetes, stroke, osteoarthritis, etc in the future. Therefore, the cell treatment including stem cell treatment will be the pillar industry which will be focused on to develop not only in China, but also in developed countries such as the United States, and it will certainly lead the new revolution in medical industry.
In addition, the Stem Cell Clinical Trial Management Approach will be issued in the second half of this year. We can believe that the support of relevant departments in China will certainly promote the regenerative medicine of stem cell to develop rapidly and normatively for the benefit of Chinese people.
Notes:
Medisun Holdings Limited: Medisun plans to invest in stem cell regenerative technology and products worldwide, focusing on cardiovascular diseases and other serious diseases, including cancer (leukemia, malignant lymphoma, etc.), lung disease, liver disease, kidney disease, diabetes, autoimmune disease, nerve system disease, stroke and spinal cord injury. Medisun is committed to uncovering the power of regenerative technology in treating human diseases and promoting it as the mainstay of future medicine.
Mayo Clinic: Headquartered in Rochester, Minnesota, USA, Mayo Clinic marks 150 years of service to patients in 2014. As a medical group with integrated treatment and care, medical school instruction and scientific research, Mayo is highly regarded by the international medical community and has been at or near the top of the U.S News & World Report list of “Best Hospitals” for more than 20 years. For more than a century, Mayo Clinic has been a leader in the research and development of new therapies, innovation in hospital maganement and next generation telemedicine, and it is sometimes referred as the “Supreme Court” of medicine. Today, Mayo Clinic has branches in Florida and Arizona, its own medical school and dozens of clinics in the surrounding states. It employs more than 3,800 physicians and scientists ans 50,900 allied health staff, with an annual revenue of nearly US$ 10 billion.
Affiliated companies established by Medisun in Asia and China
Cardio3 BioSciences Aisa Holdings Limited will be sponsoring the Phase III clinical development and commercialization of C-Cure for ischemic heart failure and other stem cell-based regenerative products. The company plans to enter the Japanese market with an expected launch of a clinical trial in 2015, followed by introduction into markets including India, Indonesia, etc. where the population is over 20 million.
Cardio3 BioSciences (China) Co., Ltd will be sponsoring the Phase III clinical development and commercialization of C-Cure in China.
Source : http://www.medisun.hk/